Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 3.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 3.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca; Foundation Medicine, Inc; and Novartis Pharmaceuticals Corporation.

Community Practice Connections™ 2nd Annual Precision Medicine Through Plasma: Using Liquid Biopsies in Contemporary Oncology Care

Release Date: February 28, 2019
Expiration Date: February 28, 2020
Media: Internet - based

Activity Overview

The emergence of novel testing strategies such as liquid biopsy has rapidly changed the treatment paradigm for patients with lung, breast, gastrointestinal, and other solid tumor malignancies. Tumor and plasma genotyping and determination of actionable genomic alterations have led to greatly improved patient outcomes; however, the potential role for liquid biopsy in screening, monitoring, and risk stratification is evolving and remains an active area of research.

In this online activity, focused on expert interviews, you will engage with medical experts in precision medicine, Benjamin P. Levy, MD; Geoffrey R. Oxnard, MD; and Joseph A. Sparano, MD; gain insight into the scientific foundations of liquid biopsy; compare the relative strengths and limitations of liquid versus tissue biopsy, including important differences in both sensitivity and specificity of the various testing methodologies; and consider the potential future opportunities for the use of liquid biopsies in cancer care.

The content and interviews are based on presentations delivered in December 2018 at the 2nd Annual Precision Medicine Through Plasma: Using Liquid Biopsies in Contemporary Oncology Care. For busy oncologists focused on the daily management of complex patients with solid tumors, this activity provides you with an opportunity to both enhance your understanding of liquid biopsy and apply the latest clinical data to the patient-care setting through case-based discussion.

Below are some clinical pearls and highlights from the activity:

  • Liquid biopsy can detect circulating tumor cells and circulating tumor DNA (ctDNA). These biomarkers have prognostic and predictive value, may reveal actionable mutations, and in patients with localized breast cancer, have a potential role in surveillance to detect early recurrence.
  • In patients with localized lung cancers, molecular residual disease detection through ctDNA analysis has been shown to identify disease recurrence significantly earlier compared with monitoring with CT imaging.
  • For patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy, cell-free DNA profiling holds promise to prospectively identify patients likely to achieve survival benefit from EGFR antibody rechallenge.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca; Foundation Medicine, Inc; and Novartis Pharmaceuticals Corporation.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is intended for medical oncologists, pathologists, and fellows who treat patients with cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer are invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  1. Compare the relative strengths and limitations of liquid biopsy against those of conventional tissue biopsy
  2. Identify the scientific foundations of liquid biopsy technology
  3. Contrast available and emerging testing technologies with respect to sensitivity, specificity, and clinical applications for patients with cancer
  4. Appraise clinical evidence pertaining to specific testing modalities that may help to individualize treatment protocols for patients with cancer

Faculty, Staff, and Planners' Disclosures


Benjamin P. Levy, MD
Benjamin P. Levy, MD
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC

Disclosures: Disclosure: Consultant: AstraZeneca, Celgene, Eli Lilly, Genentech, Merck, Takeda

Geoffrey R. Oxnard, MD
Geoffrey R. Oxnard, MD
Associate Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Disclosures: Consultant: AstraZeneca, DropWorks, GRAIL, Inivata, Loxo Oncology, Sysmex

Joseph A. Sparano, MD
Joseph A. Sparano, MD
Professor Medicine & Women’s Health
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY

Disclosures: Grant/Research Support: Deciphera Pharmaceuticals, Prescient Therapeutics; Consultant: Adgero, AstraZeneca, Celldex, Eli Lilly, Genentech/Roche, Juno, Novartis, Pfizer; Shareholder: MetaStat

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By